Reveromycin A (CAS 134615-37-5)
See product citations (1)
QUICK LINKS
Reveromycin A is investigated for its role as a natural product with bioactive properties, particularly in the study of biological pathways and cellular processes. It is a compound of interest in the field of biochemistry, where it is used to explore the mechanisms of action on a cellular level, such as the inhibition of specific enzymes or the disruption of biosynthetic pathways. Research involving reveromycin A often focuses on its unique structural features and how these contribute to its interaction with biological targets. The compound is also utilized in studies related to cell growth and proliferation, providing insights into the regulation of these processes. Additionally, reveromycin A serves as a reference compound in the synthesis of analogs which may have altered biological activities, assisting in the elucidation of structure-activity relationships.
Reveromycin A (CAS 134615-37-5) References
- Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. | Muguruma, H., et al. 2005. Clin Cancer Res. 11: 8822-8. PMID: 16361571
- Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. | Woo, JT., et al. 2006. Proc Natl Acad Sci U S A. 103: 4729-34. PMID: 16537392
- Synthesis and biological activities of reveromycin A and spirofungin A derivatives. | Shimizu, T., et al. 2008. Bioorg Med Chem Lett. 18: 3756-60. PMID: 18519164
- Reveromycin A, a new antibiotic which inhibits the mitogenic activity of epidermal growth factor. | Osada, H., et al. 1991. J Antibiot (Tokyo). 44: 259-61. PMID: 2010365
- Effect of Reveromycin A on experimental tooth movement in OPG-/- mice. | Tanaka, M., et al. 2012. J Dent Res. 91: 771-6. PMID: 22674934
- Stabilization of tooth movement by administration of reveromycin A to osteoprotegerin-deficient knockout mice. | Yabumoto, T., et al. 2013. Am J Orthod Dentofacial Orthop. 144: 368-80. PMID: 23992809
- Reveromycin A-Induced Apoptosis in Osteoclasts Is Not Accompanied by Necrosis. | Mead, B., et al. 2015. J Cell Biochem. 116: 1646-57. PMID: 25754900
- Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease. | Mizuno, M., et al. 2015. Sci Rep. 5: 16510. PMID: 26561427
- Chemical and biological studies of reveromycin A. | Osada, H. 2016. J Antibiot (Tokyo). 69: 723-730. PMID: 27270304
- Death effects of reveromycin A in normal and disease-associated cells of the joint. | Svrcina, H., et al. 2018. J Cell Biochem. 119: 4382-4396. PMID: 29077233
- Alteration of tooth movement by reveromycin A in osteoprotegerin-deficient mice. | Minamoto, C., et al. 2020. Am J Orthod Dentofacial Orthop. 157: 680-689. PMID: 32354441
- β-carboline chemical signals induce reveromycin production through a LuxR family regulator in Streptomyces sp. SN-593. | Panthee, S., et al. 2020. Sci Rep. 10: 10230. PMID: 32576869
- Inhibitory mechanism of reveromycin A at the tRNA binding site of a class I synthetase. | Chen, B., et al. 2021. Nat Commun. 12: 1616. PMID: 33712620
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Reveromycin A, 100 µg | sc-202314 | 100 µg | $188.00 | |||
Reveromycin A, 500 µg | sc-202314A | 500 µg | $426.00 |